Nektar Therapeutics (NKTR) concluded trading on Wednesday at a closing price of $1.02, with 6.09 million shares of worth about $6.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.17% during that period and on December 04, 2024 the price saw a loss of about -4.67%. Currently the company’s common shares owned by public are about 184.46M shares, out of which, 178.21M shares are available for trading.
Stock saw a price change of -4.67% in past 5 days and over the past one month there was a price change of -23.31%. Year-to-date (YTD), NKTR shares are showing a performance of 80.53% which increased to 98.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.46 but also hit the highest price of $1.93 during that period. The average intraday trading volume for Nektar Therapeutics shares is 1.45 million. The stock is currently trading -11.99% below its 20-day simple moving average (SMA20), while that difference is down -18.39% for SMA50 and it goes to -18.44% lower than SMA200.
Nektar Therapeutics (NASDAQ: NKTR) currently have 184.46M outstanding shares and institutions hold larger chunk of about 74.39% of that.
The stock has a current market capitalization of $188.15M and its 3Y-monthly beta is at 0.56. It has posted earnings per share of -$0.84 in the same period. It has Quick Ratio of 4.24 while making debt-to-equity ratio of 4.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NKTR, volatility over the week remained 6.84% while standing at 7.05% over the month.
Stock’s fiscal year EPS is expected to rise by 49.34% while it is estimated to decrease by -2.57% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on November 04, 2024 offering an Overweight rating for the stock and assigned a target price of $7 to it. Coverage by BTIG Research stated Nektar Therapeutics (NKTR) stock as a Buy in their note to investors on September 30, 2024, suggesting a price target of $4 for the stock. Stock get an Outperform rating from TD Cowen on November 09, 2023.
